(Q47450338)

16 January 2018

title

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis (English)

1 reference

16 January 2018

3

Gary Cutter

0 references

author name string

Thomas F Scott

series ordinal

1

1 reference

16 January 2018

Carol J Schramke

series ordinal

2

1 reference

16 January 2018

publication date

1 June 2003

1 reference

16 January 2018

Multiple Sclerosis Journal

published in

1 reference

16 January 2018

volume

9

1 reference

16 January 2018

issue

3

1 reference

16 January 2018

page(s)

289-292

1 reference

16 January 2018

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Randomized controlled trials to assess therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS910OA

10.1191/1352458503MS910OA

21 January 2018

Identifiers

DOI

1 reference

16 January 2018

1 reference

16 January 2018